From the Journals

Novel anti-PD-1 antibody can be given subcutaneously


 

FROM JAMA ONCOLOGY

The novel anti–programmed cell death antibody PF-06801591 had tolerable safety and efficacy outcomes when given subcutaneously to patients with advanced solid tumors, based on results from an ongoing phase 1 trial.

“We assessed feasibility of monthly subcutaneous administration of PF-06801591, a humanized immunoglobulin G4 monoclonal antibody that binds to the programmed cell death [PD-1] receptor,” Melissa L. Johnson, MD, of the Sarah Cannon Research Institute, Nashville, Tenn., and colleagues wrote in JAMA Oncology. “Subcutaneous administration of an anti-PD-1 antibody in patients with advanced solid tumors appears to be feasible.”

The researchers evaluated the efficacy, safety, and pharmacokinetics of the novel anti-PD-1 therapy in a group of 40 patients with locally advanced or metastatic solid tumors. The antibody was administered in both subcutaneous and intravenous forms.

Study participants were administered the subcutaneous form of the antibody at 300 mg every 4 weeks or the intravenous form at 0.5, 1, 3, or 10 mg/kg every 3 weeks.

“Dose escalation occurred after two to four patients were enrolled per dose level, with additional patients enrolled in each cohort for further assessment,” the researchers wrote.

The primary endpoints were safety and dose-limiting adverse effects. Efficacy, immunogenicity, pharmacokinetics, and PD-1 receptor occupancy were secondary endpoints.

After analysis, Dr. Johnson and colleagues reported that the overall response rate was 18.4%. In addition, no dose-limiting toxicities were detected in both intravenous and subcutaneous groups, but grade 3 or greater adverse events were reported in 6.7% and 16% of patients treated with subcutaneous and intravenous dosage forms, respectively.

“No dose–adverse event associations were observed during intravenous dose escalation, and no serious skin toxic effects occurred with subcutaneous delivery,” they reported.

Based on the findings, the team selected the subcutaneous form (300 mg) of the therapy for additional assessment in the second half of this ongoing trial.

The study was funded by Pfizer. The authors reported financial affiliations with BerGenBio, EMD Serono, Janssen, Mirati Therapeutics, Pfizer, and several others.

SOURCE: Johnson ML et al. JAMA Oncol. 2019 May 30. doi: 10.1001/jamaoncol.2019.0836.

Recommended Reading

PACIFIC: Patient-reported outcomes unaffected by PD-L1 expression
MDedge Hematology and Oncology
Monitoring, early intervention key to CAR T safety
MDedge Hematology and Oncology
Lessons from KEYNOTE-158 and the role of R-CHOP
MDedge Hematology and Oncology
ICYMI: NIH renames, streamlines gene therapy committee
MDedge Hematology and Oncology
MYSTIC trial: bTMB correlates with tTMB, predicts survival in mNSCLC
MDedge Hematology and Oncology
High pCR rate in HPV+ HNSCC with nivolumab/SBRT
MDedge Hematology and Oncology
SRA737 + anti–PD-L1 therapy and low-dose gemcitabine shows early promise for SCLC
MDedge Hematology and Oncology
Myc signaling, monocytes predict NSCLC response to second-line entinostat + pembro
MDedge Hematology and Oncology
CMS proposes payment increase for administering CAR T in the hospital
MDedge Hematology and Oncology
Do some EGFR mutation subtypes benefit from immune checkpoint blockade?
MDedge Hematology and Oncology